Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.

Butler CC. et al, (2022), Lancet

An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study

Richards D. et al, (2022), Orphanet journal of rare diseases, 17

In vivo human keyhole limpet hemocyanin challenge in early phase drug development: A systematic review.

Drennan PG. et al, (2022), Clin transl sci

In vivo human keyhole limpet haemocyanin challenge in early phase drug development: A systematic review

Drennan P. et al, (2022), Clinical and translational science

Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial

Butler C. et al, (2022)

Predictive validity in drug discovery: what it is, why it matters and how to improve it

RICHARDS D., (2022), Nature reviews drug discovery

Corrigendum to 'Multiple endocrine neoplasia type 1 in children and adolescents: Clinical features and treatment outcomes' [Surgery 171 (2021) 77-87].

Shariq OA. et al, (2022), Surgery

COVID-19 therapeutics: challenges and directions for the future

Robinson PC. et al, (2022), Proceedings of the national academy of sciences

Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial.

Dorward J. et al, (2022), Br j gen pract

Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.

Wechalekar A. et al, (2022), Bmc cardiovasc disord, 22

Colchicine for COVID-19 in adults in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial

PRINCIPLE Trial Collaborative Group None. et al, (2022)

Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

Fisher BA. et al, (2021), The lancet respiratory medicine

CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults.

Veenith T. et al, (2021), Bmj open, 11

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.

Yu L-M. et al, (2021), Lancet

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial.

Hinks TSC. et al, (2021), Lancet respir med

Namilumab or infliximab compared to standard of care in hospitalised patients with COVID-19 (CATALYST): a phase 2 randomised adaptive trial

Fisher BA. et al, (2021)

Drug Discovery and Development Technology in Transition

Hill RG. and Richards D., (2021)

Multiple Endocrine Neoplasia Type 1 in Children and Adolescents: Clinical Features and Treatment Outcomes

SHARIQ O. and RICHARDS D., (2021), Surgery

A Randomised Clinical Trial of Azithromycin Versus Standard Care in Ambulatory COVID-19 – The ATOMIC2 Trial

Hinks TSC. et al, (2021), Ssrn electronic journal

CATALYST trial protocol: A multicentre, open-label, phase II, multi-arm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults

Veenith T. et al, (2021)

Load More

Include forthcoming?